Orchard Therapeutics Future Growth
Future criteria checks 2/6
Orchard Therapeutics is forecast to grow earnings and revenue by 12.5% and 34.5% per annum respectively while EPS is expected to grow by 55.2% per annum.
Key information
12.5%
Earnings growth rate
55.2%
EPS growth rate
| Biotechs earnings growth | 26.7% |
| Revenue growth rate | 34.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Dec 2023 |
Recent future growth updates
Recent updates
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR
Jan 19Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price
May 09
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
Mar 10Orchard Therapeutics: Gene Therapy For Rare Child Disease
Aug 19Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M
Aug 04Orchard Therapeutics: Shadow Of Former Glory
Jan 20Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
Aug 16Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?
Jun 14What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?
Feb 03Orchard Therapeutics appoints Braden Parker as chief commercial officer
Jan 29Orchard Therapeutics' OTL-200 wins FDA's RMAT status
Jan 14Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022
Jan 12Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?
Jan 08Orchard Therapeutics' MLD gene therapy wins European nod
Dec 21Our View On Orchard Therapeutics
Dec 17Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year
Dec 11Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study
Dec 08Orchard Therapeutics (ORTX) Investor Presentation - Slideshow
Nov 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 152 | -50 | -106 | N/A | 2 |
| 12/31/2025 | 97 | -75 | -148 | N/A | 2 |
| 12/31/2024 | 54 | -115 | -129 | -114 | 3 |
| 12/31/2023 | 28 | -93 | -85 | -85 | 3 |
| 9/30/2023 | 22 | -73 | -94 | -93 | N/A |
| 6/30/2023 | 21 | -85 | -93 | -87 | N/A |
| 3/31/2023 | 18 | -124 | -93 | -86 | N/A |
| 12/31/2022 | 23 | -151 | -83 | -76 | N/A |
| 9/30/2022 | 16 | -179 | -104 | -97 | N/A |
| 6/30/2022 | 12 | -168 | -100 | -96 | N/A |
| 3/31/2022 | 7 | -154 | -109 | -105 | N/A |
| 12/31/2021 | 2 | -145 | -128 | -125 | N/A |
| 9/30/2021 | 1 | -142 | -106 | -104 | N/A |
| 6/30/2021 | 2 | -126 | -115 | -114 | N/A |
| 3/31/2021 | 3 | -137 | -117 | -116 | N/A |
| 12/31/2020 | 3 | -152 | -139 | -126 | N/A |
| 9/30/2020 | 3 | -164 | -171 | -155 | N/A |
| 6/30/2020 | 3 | -180 | -197 | -181 | N/A |
| 3/31/2020 | 3 | -183 | -187 | -172 | N/A |
| 12/31/2019 | 3 | -163 | -170 | -166 | N/A |
| 9/30/2019 | 3 | -143 | -153 | -151 | N/A |
| 6/30/2019 | 2 | -140 | -131 | -130 | N/A |
| 3/31/2019 | 2 | -246 | -129 | -127 | N/A |
| 12/31/2018 | 2 | -230 | -102 | -98 | N/A |
| 9/30/2018 | 1 | -219 | -85 | -81 | N/A |
| 6/30/2018 | N/A | -198 | -63 | -59 | N/A |
| 3/31/2018 | N/A | -48 | -43 | -40 | N/A |
| 12/31/2017 | N/A | -40 | -34 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ORTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ORTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ORTX's revenue (34.5% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: ORTX's revenue (34.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ORTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/24 13:14 |
| End of Day Share Price | 2024/01/24 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orchard Therapeutics plc is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Duncan | Cantor Fitzgerald & Co. |
| Emma Nealon | Cantor Fitzgerald & Co. |
| Graig Suvannavejh | Goldman Sachs |